Hudson Bay Capital Management
PCVX icon

Hudson Bay Capital Management’s Vaxcyte PCVX Stock Holding History

Hudson Bay Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62M Buy
45,000
+14,030
+45% +$762K 0.01% 749
2026
Q1 		$1.8M Buy
+30,970
New +$1.68M 0.01% 784
2025
Q2 		– Sell
-144,309
Closed -$5.45M – 1602
2025
Q1 		$5.45M Buy
144,309
+45,570
+46% +$3.64M 0.02% 571
2024
Q4 		$8.08M Buy
+98,739
New +$9.8M 0.03% 404

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Hudson Bay Capital Management's PCVX Position: Q2 2026 in Review

Hudson Bay Capital Management increased its Vaxcyte (PCVX) stake by 45% in Q2 2026, buying an estimated $762K and bringing the position to 45,000 shares worth $2.62M. The position accounts for 0.01% of the portfolio, ranked #749.

Hudson Bay Capital Management first reported a position in PCVX in Q4 2024 and has held it in 4 quarters since. The position peaked at $8.08M in Q4 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Hudson Bay Capital Management held 45,000 shares of Vaxcyte worth $2.62M as of Q2 2026.
  • Hudson Bay Capital Management bought 14,030 Vaxcyte shares in Q2 2026, an estimated $762K.
  • Vaxcyte made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #749 holding.
  • Hudson Bay Capital Management first reported a position in Vaxcyte in Q4 2024 and has held it in 4 quarters since.
  • Hudson Bay Capital Management's Vaxcyte position peaked at $8.08M in Q4 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.